Jeffery S. Russell,
MD, PhD, MBA
Languages Spoken: English
Dr. Russell is a medical oncologist and treats patients with head and neck, endocrine, cutaneous, and other rare or unknown primary malignancies. He started his practice at Moffit Cancer Center in Tampa, FL and then spend a few years working in the pharmaceutical industry helping to develop cutting-edge immune therapy evaluated in clinical trials. He has recently joined the excellent Head and Neck Team at Huntsman and is excited to be working with patients again.
Clinical Locations
801-646-4093
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor (Clinical) |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
5.0/ 5
Care provider's explanation of condition/problem
5.0/ 5
Care provider's effort to include me in decisions
5.0/ 5
Wait time at clinic
4.7/ 5
Care provider's concern for questions & worries
5.0/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
October 15, 2022
HUNTSMAN CANCER CENTER
I would give high marks for how I was treated
UofU Patient
October 13, 2022
HUNTSMAN CANCER CENTER
Feel very well cared for by Dr Russell
UofU Patient
October 09, 2022
HUNTSMAN CANCER CENTER
Covered everything and very informative!
UofU Patient
September 19, 2022
HUNTSMAN CANCER CENTER
Both providers, Drs Hyngstrom and Russell, were informative, caring, and proactive. They both came in prepared to discuss the specifics of my case and future actions based on my outcomes and lab results.
UofU Patient
September 18, 2022
HUNTSMAN CANCER CENTER
Answered all of my questions
UofU Patient
September 17, 2022
HUNTSMAN CANCER CENTER
I would highly recommend this doctor and staff
UofU Patient
September 06, 2022
HUNTSMAN CANCER CENTER
We are so blessed and grateful for the compassion and care that both Dr. Russell and Lexi have continually shown.
UofU Patient
September 06, 2022
HUNTSMAN CANCER CENTER
Dr Russell and his staff are good at explaining what is going on. They are very caring.
UofU Patient
September 03, 2022
HUNTSMAN CANCER CENTER
Dr. Russell is a fantastic doctor. He never rushes and always answers all my questions.
UofU Patient
August 20, 2022
HUNTSMAN CANCER CENTER
Dr Russell is fantastic
UofU Patient
August 14, 2022
HUNTSMAN CANCER CENTER
Dr. Jeff Russell is great.
UofU Patient
August 11, 2022
HUNTSMAN CANCER CENTER
Dr Russell and his team spend a lot of time with me asking questions and explaining everything very thoroughly. I am always impressed.
UofU Patient
August 06, 2022
HUNTSMAN CANCER CENTER
Doctor Russell is always professional and shows genuine concern for me
UofU Patient
July 30, 2022
HUNTSMAN CANCER CENTER
I would highly recommend my provider
UofU Patient
July 18, 2022
HUNTSMAN CANCER CENTER
Excellent
UofU Patient
July 09, 2022
HUNTSMAN CANCER CENTER
Dr. Russell is fantastic.
UofU Patient
July 03, 2022
SOUTH JORDAN HEALTH CENTER
Did not get pre-infusion meds, although they claimed to have sent them to my pharmacy
UofU Patient
June 30, 2022
HUNTSMAN CANCER CENTER
Dr. Russell is very patient to listen to any questions or concerns I have. He doesn't act like he's in a hurry, like he needs to rush off to his next appointment. He takes the time that I need for him to explain things to me, and always explains things in a way that I can understand. I always feel like both he and his nurse really care about how I'm doing and want to help.
UofU Patient
June 27, 2022
HUNTSMAN CANCER CENTER
My doctor provided a comprehensive long-term plan for monitoring any possible return of my cancer.
UofU Patient
June 25, 2022
HUNTSMAN CANCER CENTER
Genuinely interested in my welfare
UofU Patient
June 25, 2022
HUNTSMAN CANCER CENTER
Dr Russell is so knowledgeable and professional
UofU Patient
June 14, 2022
HUNTSMAN CANCER CENTER
Great Doctor
UofU Patient
June 13, 2022
HUNTSMAN CANCER CENTER
Good
UofU Patient
June 02, 2022
HUNTSMAN CANCER CENTER
Dr. Russell listened very carefully, and gave clear and understandable answers to all of my concerns.
UofU Patient
May 28, 2022
HUNTSMAN CANCER CENTER
I would highly recommend my care provider
UofU Patient
May 20, 2022
HUNTSMAN CANCER CENTER
Dr Russell cared
UofU Patient
May 16, 2022
HUNTSMAN CANCER CENTER
My doctor provided a comprehensive explanation of the status of my condition, answered all my questions, and followed up with emails.
UofU Patient
May 14, 2022
HUNTSMAN CANCER CENTER
Information and dialogue were excellent.
UofU Patient
May 09, 2022
HUNTSMAN CANCER CENTER
Alyssa Erickson-Wayman & Dr. Russel are the BEST!
UofU Patient
May 05, 2022
HUNTSMAN CANCER CENTER
Dr Russell always have explains options and is thorough and caring
UofU Patient
April 30, 2022
HUNTSMAN CANCER CENTER
Always had excellent service at Huntsman.
UofU Patient
April 30, 2022
HUNTSMAN CANCER CENTER
Great provider. I would give the doctor and staff a high recommendation
UofU Patient
April 29, 2022
SOUTH JORDAN HEALTH CENTER
I usually don't recommend oncologists
UofU Patient
April 23, 2022
HUNTSMAN CANCER CENTER
Dr. Russell is very thorough, a good listener, knowledgeable, caring, and delivers the type and amount of information I need to be informed about my current and future treatments. I feel very lucky to have him as my general oncologist! :)
UofU Patient
April 23, 2022
HUNTSMAN CANCER CENTER
Doctor Is amazing at discussing, explaining & listening to all concerns. He is quick to respond to any needs. A great doctor!
UofU Patient
April 21, 2022
HUNTSMAN CANCER CENTER
Dr. Russell was very caring and informative.
UofU Patient
April 12, 2022
HUNTSMAN CANCER CENTER
I'm a Jeff Russell fan all day, but would recommend that Drs coordinate how news is delivered to patients. News of the severity of my needs and treatments came out over a series of meetings and they all seemed surprised that I hadn't been informed.
UofU Patient
April 09, 2022
HUNTSMAN CANCER CENTER
Dr Russell is very informative and kind
UofU Patient
April 02, 2022
HUNTSMAN CANCER CENTER
Great Doctor.
UofU Patient
April 02, 2022
HUNTSMAN CANCER CENTER
Dr Russell is very well informed on my needs. He cares about my feelings and recommends what he feels is best for me. He listens to me & my family to achieve the best options.
UofU Patient
March 26, 2022
HUNTSMAN CANCER CENTER
Dr Russell is great
UofU Patient
March 19, 2022
HUNTSMAN CANCER CENTER
Great Doctor. The procedure was explained and the side effects were explained.
UofU Patient
March 07, 2022
HUNTSMAN CANCER CENTER
Dr Russell always answers all of my questions and offers explanations and talked at length about my care plan.
UofU Patient
March 07, 2022
HUNTSMAN CANCER CENTER
Excellent .. Answered all questions thoroughly
UofU Patient
February 28, 2022
HUNTSMAN CANCER CENTER
Dr. Russell is an excellent physician
UofU Patient
February 21, 2022
HUNTSMAN CANCER CENTER
Dr. Russell and staff have made my cancer journey smooth. I've always been informed and educated of every step in advance.
UofU Patient
February 05, 2022
HUNTSMAN CANCER CENTER
I would highly recommend Dr. Russell as a provider to all cancer patients
UofU Patient
February 01, 2022
HUNTSMAN CANCER CENTER
Dr Russell is very concerned caring and informative through this entire process. He answers questions thoroughly and makes certain I understand the whole procedure and timeline .
UofU Patient
January 20, 2022
HUNTSMAN CANCER CENTER
All good
UofU Patient
January 08, 2022
HUNTSMAN CANCER CENTER
Wonderful Doctor
Dr. Russell is a medical oncologist and treats patients with head and neck, endocrine, cutaneous, and other rare or unknown primary malignancies. He started his practice at Moffit Cancer Center in Tampa, FL and then spend a few years working in the pharmaceutical industry helping to develop cutting-edge immune therapy evaluated in clinical trials. He has recently joined the excellent Head and Neck Team at Huntsman and is excited to be working with patients again.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor (Clinical) |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) |
Education History
| Graduate Training | Temple University Strategic Management M.B.A., 2020 |
| Fellowship | Stanford University School of Medicine Medical Oncology Fellow, 2013 |
| Internship/Residency | University of California, San Francisco School of Medicine Internal Medicine Intern/Resident, 2010 |
| Professional Medical | University of Texas Health Science Center at San Antonio Medicine M.D., 2007 |
| Graduate Training | University of Texas Health Science Center at Houston, University of Texas MD Anderson Cancer Center Biomedical Sciences/Radiation Biology Ph.D., 2002 |
| Graduate Training | University of Miami Biomedical Engineering M.S., 1997 |
| Undergraduate | University of Kansas Electrical Engineering B.S., 1995 |
Selected Publications - Journal Articles
Journal Article
- Lambert J, Marrel A, DAngelo SP, Burgess MA, Chmielowski B, Fazio N, Gambichler T, Grob JJ, Lebb C, Robert C, Russell J, Gzel G, Bharmal M (2020). Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. Patient, 13(4), 457-467.
- Knepper TC, Montesion M, Russell JS, Sokol ES, Frampton GM, Miller VA, Albacker LA, McLeod HL, Eroglu Z, Khushalani NI, Sondak VK, Messina JL, Schell MJ, DeCaprio JA, Tsai KY, Brohl AS (2019). The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clin Cancer Res, 25(19), 5961-5971.
- Wang HL, McMillan SC, Vijayakumar N, McDonald S, Huang LT, Gwede C, Padhya T, Russell J, Vondruska K, Buck HG, Huang Y, Visovsky C (2018). A Behavioral Physical Activity Intervention to Manage Moderate and Severe Fatigue Among Head and Neck Cancer Patients-Pre-efficacy Study in the National Institutes of Health ORBIT Model. Cancer Nurs, 42(1), E1-E14.
- Naghavi AO, Echevarria MI, Strom TJ, Abuodeh YA, Venkat PS, Ahmed KA, Demetriou S, Frakes JM, Kim Y, Kish JA, Russell JS, Otto KJ, Chung CH, Harrison LB, Trotti A, Caudell JJ (2018). Patient choice for high-volume center radiation impacts head and neck cancer outcome. Cancer Med, 7(10), 4964-4979.
- DAngelo SP, Russell J, Lebb C, Chmielowski B, Gambichler T, Grob JJ, Kiecker F, Rabinowits G, Terheyden P, Zwiener I, Bajars M, Hennessy M, Kaufman HL (2018). Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA Oncol, 4(9), e180077.
- Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, DAngelo SP, Shih KC, Lebb C, Milella M, Brownell I, Lewis KD, Lorch JH, von Heydebreck A, Hennessy M, Nghiem P (2018). Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer, 6(1), 7.
- Ross JS, Gay LM, Wang K, Vergilio JA, Suh J, Ramkissoon S, Somerset H, Johnson JM, Russell J, Ali S, Schrock AB, Fabrizio D, Frampton G, Miller V, Stephens PJ, Elvin JA, Bowles DW (2017). Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. Ann Oncol, 28(10), 2539-2546.
- Knepper TC, Freeman ML, Gibney GT, McLeod HL, Russell JS (2017). Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma. JAMA Dermatol, 153(6), 607-609.
- Strom T, Naghavi AO, Messina JL, Kim S, Torres-Roca JF, Russell J, Sondak VK, Padhya TA, Trotti AM, Caudell JJ, Harrison LB (2016). Improved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck. Head Neck, 39(1), 48-55.
- Strom TJ, Naghavi AO, Trotti AM, Russell J, Kish JA, McCaffrey J, Otto KJ, Harrison LB, Caudell JJ (2016). Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years. J Geriatr Oncol, 8(1), 50-55.
- Wang K, Russell JS, McDermott JD, Elvin JA, Khaira D, Johnson A, Jennings TA, Ali SM, Murray M, Marshall C, Oldham DS, Washburn D, Wong SJ, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Serracino HS, Ross JS, Bowles DW (2016). Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations. Clin Cancer Res, 22(24), 6061-6068.
- Lowry PA, Freeman ML, Russell JS (2016). Nursing Management of Advanced Merkel Cell Carcinoma. Oncol Nurs Forum, 43(6), 680-683.
- Strom T, Carr M, Zager JS, Naghavi A, Smith FO, Cruse CW, Messina JL, Russell J, Rao NG, Fulp W, Kim S, Torres-Roca JF, Padhya TA, Sondak VK, Trotti AM, Harrison LB, Caudell JJ (2016). Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma. Ann Surg Oncol, 23(11), 3572-3578.
- Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, DAngelo SP, Shih KC, Lebb C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P (2016). Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol, 17(10), 1374-1385.
- Valderrabano P, Montilla-Soler J, Mifsud M, Leon M, Centeno B, Khazai L, Padhya T, McCaffrey T, Russell J, McIver B, Otto K (2016). Hypermetabolism on (18)F-Fluorodeoxyglucose Positron Emission Tomography Scan Does Not Influence the Interpretation of Thyroid Cytopathology, and Nodules with a SUVmax <2.5 Are Not at Increased Risk for Malignancy. Thyroid, 26(9), 1300-7.
- Valderrabano P, Leon ME, Centeno BA, Otto KJ, Khazai L, McCaffrey JC, Russell JS, McIver B (2016). Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests. Eur J Endocrinol, 174(5), 621-9.
- Frakes JM, Naghavi AO, Demetriou SK, Strom TJ, Russell JS, Kish JA, McCaffrey JC, Otto KJ, Padhya TA, Harrison LB, Trotti AM, Caudell JJ (2015). Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer. Cancer, 122(4), 634-41.
- Strom TJ, Trotti AM, Kish J, Russell JS, Rao NG, McCaffrey J, Padhya TA, Otto KJ, Caudell JJ (2015). Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer. Oral Oncol, 51(7), 704-8.
- Metterle L, Russell JS, Patel NS (2015). An overview of the medical management of nonmelanoma skin cancer. Curr Probl Cancer, 39(4), 226-36.
- Russell JS, Brown JM (2014). Circulating mouse Flk1+/c-Kit+/CD45- cells function as endothelial progenitors cells (EPCs) and stimulate the growth of human tumor xenografts. Mol Cancer, 13, 177.
- Russell JS, Brown JM (2013). The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. Front Physiol, 4, 157.
- Russell JS, Colevas AD (2012). The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck. Chemother Res Pract, 2012, 761518.
- Russell JS, Sawhney R, Monto A, Nanavati S, Davoren JB, Aslam R, Corvera CU (2010). Periprocedural complications by Child-Pugh class in patients undergoing transcatheter arterial embolization or chemoembolization to treat unresectable hepatocellular carcinoma at a VA medical center. Am J Surg, 200(5), 659-64.
- Camphausen K, Brady KJ, Burgan WE, Cerra MA, Russell JS, Bull EE, Tofilon PJ (2004). Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci. Mol Cancer Ther, 3(4), 409-16.
- Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K, Tofilon PJ (2003). Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res, 63(21), 7377-83.
- Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ (2003). Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res, 9(10 Pt 1), 3749-55.
- Russell JS, Tofilon PJ (2002). Radiation-induced activation of nuclear factor-kappaB involves selective degradation of plasma membrane-associated I(kappa)B(alpha). Mol Biol Cell, 13(10), 3431-40.
- Russell JS, Raju U, Gumin GJ, Lang FF, Wilson DR, Huet T, Tofilon PJ (2002). Inhibition of radiation-induced nuclear factor-kappaB activation by an anti-Ras single-chain antibody fragment: lack of involvement in radiosensitization. Cancer Res, 62(8), 2318-26.
- Russell JS, Lang FF, Huet T, Janicot M, Chada S, Wilson DR, Tofilon PJ (1999). Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment. Cancer Res, 59(20), 5239-44.
- Wu X, Ting JY, Markoe AM, Landy HJ, Fiedler JA, Russell J (1996). Stereotactic dose computation and plan optimization using the convolution theorem. I. Dose computation. Stereotact Funct Neurosurg, 66 Suppl 1, 302-8.